REUTERS
October 12, 2020 at 18:10 JST
A health official wearing protective gear gives surveys to people waiting for the COVID-19 test at a public health center in Goyang, South Korea, on May 28. (AP Photo)
SEOUL--South Korean drugmaker Daewoong Pharmaceutical Co. Ltd. said on Monday that it had received regulatory approval for Phase 1 clinical trials of its anti-parasitic niclosamide drug to treat COVID-19 patients.
The approval comes after the company in August received Indian regulatory approval to test the drug in Phase 1 trials.
The company confirmed the safety of the drug in its latest study in partnership with New Delhi-based Mankind Pharma Ltd., Daewoong said in a statement.
In September, Daewoong separately launched another overseas human trial of the drug in the Philippians.
Daewoong plans to seek conditional approval for its anti-viral drug, DWRX2003, for emergency use after securing the results from a second-stage clinical study, the company said.
Daewoong had said its anti-viral drug had completely eliminated the novel coronavirus from animals’ lungs during pre-clinical testing.
S. Korea firm says anti-parasitic drug works against coronavirus in animal tests
June 9, 2020
S. Korea’s Daewoong Pharma gets India nod to test anti-parasite drug for COVID-19
August 11, 2020
Ministry speeds approval process for Avigan to treat COVID-19
May 13, 2020
Ministry nod for Avigan to treat COVID-19 not in cards yet
May 26, 2020
Steroid drug dexamethasone approved to treat virus patients
July 22, 2020
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
A peek through the music industry’s curtain at the producers who harnessed social media to help their idols go global.
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series about Japanese-Americans and their memories of World War II
